Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.
about
A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy.Comparison of soymilk and probiotic soymilk effects on serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in diabetic Wistar rats.Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice.Coadministration of alloxan and nicotinamide in rats produces biochemical changes in blood and pathological alterations comparable to the changes in type II diabetes mellitus.
P2860
Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Population pharmacodynamic mod ...... tment in STZ/NA diabetic rats.
@en
type
label
Population pharmacodynamic mod ...... tment in STZ/NA diabetic rats.
@en
prefLabel
Population pharmacodynamic mod ...... tment in STZ/NA diabetic rats.
@en
P2093
P2860
P356
P1476
Population pharmacodynamic mod ...... tment in STZ/NA diabetic rats.
@en
P2093
Donald E Mager
Leonid Kagan
P2860
P304
P356
10.1002/JPS.23682
P407
P577
2013-07-29T00:00:00Z